Outcome of Pregnancy in the Era of Pegylated Interferon Alpha 2a in Females with Essential Thrombocythemia: An Experience from Qatar

Mohammad Abu-Tineh; Nancy Kassem; Mohammad Abdul-Jaber Abdulla; Omar Mohammad Ismail; Rola Ghasoub; Mahmood B Aldapt; Mohamed A Yassin

doi:10.1159/000506447

Outcome of Pregnancy in the Era of Pegylated Interferon Alpha 2a in Females with Essential Thrombocythemia: An Experience from Qatar

Case Rep Oncol. 2020 Mar 26;13(1):336-340. doi: 10.1159/000506447. eCollection 2020 Jan-Apr.

Authors

Mohammad Abu-Tineh¹, Nancy Kassem², Mohammad Abdul-Jaber Abdulla³, Omar Mohammad Ismail³, Rola Ghasoub², Mahmood B Aldapt³, Mohamed A Yassin³

Affiliations

¹ Department of Medical Education, Hamad Medical Corporation (HMC), Doha, Qatar.
² National Center for Cancer Care and Research, Department of Pharmacy, HMC, Doha, Qatar.
³ National Center for Cancer Care and Research, Department of Oncology - Hematology and BMT Section -, HMC, Doha, Qatar.

Abstract

Myeloproliferative neoplasms are a diversified group of diseases of the hematopoietic stem cell, such as essential thrombocythemia (ET) and polycythemia vera. They are mainly caused by mutations in the following genes: JAK2, CALR, and MPL. All carry an increased risk to transform into acute leukemia or chronic myelogenous leukemia along with thrombosis and hemorrhagic complications. Treatment of such disorders during pregnancy is a challenging footstep, given the high risk of complications for both the mother and the fetus. Here, we report about two pregnant females with ET that has been treated with pegylated interferon alpha with safe and effective outcome.

Keywords: Essential thrombocythemia; Interferon; Myeloproliferative neoplasms; PEG-IFN alpha-2A; Pregnancy.

Publication types

Case Reports